Preliminary data shows an increase of potency of the company’s first product candidate, DXL625 (CD20), for the prospective treatment of non-Hodgkin’s lymphoma. The study compared DXL625 with a control vehicle and Genentech’s Rituxan. Additional results demonstrated DXL625 more potently induced apoptosis (cell suicide) in B-cell lymphoma cells and B-cell leukemia (hairy cells).
Thomas Kindt, chief scientific officer of InNexus, said: “Studies done at InNexus have also discovered that DXL625 has greater killing potency than Rituxan in cell lines of both moderate and low expressors of CD20, the target used to attack NHL.”